Intellia Therapeutics, Inc.

NTLA Nasdaq CIK: 0001652130

Company Information

Industry In Vitro & In Vivo Diagnostic Substances
SIC Code 2835
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 40 ERIE STREET, CAMBRIDGE, MA, 02139
Mailing Address 40 ERIE STREET, CAMBRIDGE, MA, 02139
Phone 857-285-6200
Fiscal Year End 1231
EIN 364785571

Financial Overview

FY2025

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G/A Passive ownership amendment March 27, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
8-K Current report of material events March 2, 2026 View on SEC
424B5 Prospectus supplement March 2, 2026 View on SEC

Material Events

8-K Strategy Change March 2, 2026
High Impact
  • FDA lifted clinical hold on MAGNITUDE trial for nexiguran ziclumeran (nex-z), Intellia's lead drug candidate.
  • Expanded 'at-the-market' (ATM) stock offering program by $400 million, increasing total potential capital to $1 billion.
View Analysis

Insider Trading

SELL 8 insiders 13 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2835)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.